Sections
Thank you for your interest in Cell Proliferation. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting on symposium.
Free Format submission
Cell Proliferation now offers Free Format submission for a simplified and streamlined submission process.
Before you submit, you will need:
New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/CPR. You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the "My Submissions" button. For technical help with the submission system, please review our FAQs or contact [email protected].
For help with submissions, please contact: [email protected]
We look forward to your submission.
Data Protection and Privacy
By submitting a manuscript to, or reviewing for, this publication, your name, email address, institutional affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Preprint Policy
Cell Proliferation accepts articles previously published on preprint servers. It also considers for review articles previously available as preprints. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.
Please find the Wiley preprint policy here.
Cell Proliferation is a journal devoted to studies into all aspects of cell proliferation and differentiation in normal and abnormal states; control systems and mechanisms operating at inter- and intracellular, molecular and genetic levels; modification by and interactions with chemical and physical agents; mathematical modelling; and the development of new techniques. In addition to original research papers Cell Proliferation publishes invited review articles, book reviews and letters commenting on previously published papers and/or topics of general interest.
Cell Proliferation is your complete reference for research relating to: stem cells, regenerative medicine, tissue engineering, cell cycle control, cell senescence, cell death and mathematical modelling. This journal is considered essential reading for those involved in cancer research and stem cell research. It is devoted to the study of cell proliferation and differentiation in normal and abnormal states – covering such aspects as; the construction of models for reaction mechanisms, and the study of microenvironmental factors on reaction rates, including work on new developments in techniques and the mathematical interpretation of data. The readership consists of professional research workers in the fields of experimental biology and oncology.
Cell Proliferation publishes a number of different article types including:
|
Article Type |
Description |
Word Limit |
Abstract / Structure |
Other Requirements |
|
Original Article |
Reports of new research findings or conceptual analyses that make a significant contribution to knowledge. |
Up to 4000w, excluding references |
Unstructured |
Author Contribution Data Availability Statement Conflict of Interest IRB Statement |
| Review Article |
Critical reviews of the literature, including systematic reviews and meta-analyses. |
Up to 6,000 words, excluding references |
Unstructured |
Author Contribution Conflict of Interest |
|
Brief Report |
Preliminary findings of research in progress or a case report of particular interest |
Up to 2000w |
Unstructured |
Author Contribution Data Availability Statement Conflict of Interest IRB Statement |
|
Letter to the Editors |
A letter, or response to a letter, sent to the journal to raise a point of interest, discuss a different opinion or encourage participation |
Up to 2000w |
|
Author Contribution Conflict of Interest |
|
Standards |
Public statement of what a representative group of experts agree to be evidence-based and state-of-the-art knowledge on an aspect of practice/policy. |
Up to 2000w |
Unstructured |
Author Contribution Conflict of Interest |
|
Editorial |
An opinion or overview of an issue by the editors or someone invited by editors. Unsolicited material may be considered. Please approach the Editorial Office ([email protected]) before submitting this material. |
Up to 1000w |
|
|
|
Meeting Report |
Summary of developments presented at a meeting, relying largely on the works presented at the meeting, rather than being fully referenced accounts of a field. |
Up to 1500w |
|
Conflict of Interest |
|
Abstracts |
Abstracts published as articles, either individually, under sections, or as an entire collection from a conference, and materials related to them, such as Introductions, Author Indices etc. |
Up to 5000w |
|
Conflict of Interest |
|
Commentary |
Summary of developments presented at a meeting, relying largely on the works presented at the meeting, rather than being fully referenced accounts of a field. |
Up to 1500w |
|
Conflict of Interest |
Editorial Review and Acceptance
The acceptance criteria for all papers is the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements. Wiley's policy on confidentiality of the review process is available here.
Data Sharing and Data Accessibility
Cell Proliferation recognizes the many benefits of archiving research data. The journal expects you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles (https://www.force11.org/group/fairgroup/fairprinciples). All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the data then you must provide the appropriate data availability statement. Cell Proliferation notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary). Sample statements are available here. If published, all statements will be placed in the heading of your manuscript.
Data Citation
Please also cite the data you have shared, like you would cite other sources that your article refers to, in your references section. You should follow the format for your data citations laid out in the Joint Declaration of Data Citation Principles, https://www.force11.org/datacitationprinciples:
[dataset] Authors; Year; Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI)
Graphical Abstract
Graphical Abstract is mandatory for original article or review article, while optional for other article types. It is a single, concise visual summary of the main topics and if possible key findings of the article to draw the reader to the whole paper. Please prepare the Graphical Abstract within the dimensions of 50 mm x 60 mm as an Image File, ideally in color at a minimum resolution of 300 dpi.
Graphical Abstracts can be shared and reproduced via all social media without limitation, for the benefit of spreading important research information.
Authors are responsible for obtaining permission to use any images that they include from outside sources, including articles, web pages, stock photo sites or Google image searches. Any needed permissions must be submitted along with your graphical abstract or identified in the Acknowledgements section of your manuscript.
Human Studies and Subjects
For manuscripts reporting medical studies involving human participants, we require a statement identifying the ethics committee that approved the study, and that the study conforms to recognized standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.
Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher, however in signing the author license to publish authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available.
Animal Studies
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:
• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.
Clinical Trial Registration
We require that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.
Research Reporting Guidelines
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. We encourage authors to adhere to the following research reporting standards.
• CONSORT
• SPIRIT
• PRISMA
• PRISMA-P
• STROBE
• CARE
• COREQ
• STARD and TRIPOD
• CHEERS
• the EQUATOR Network
• Future of Research Communications and e-Scholarship (FORCE11)
• ARRIVE guidelines
• National Research Council's Institute for Laboratory Animal Research guidelines: the Gold Standard Publication Checklist from Hooijmans and colleagues
• Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website; Biosharing website
• REFLECT statement
Species Names
Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, the scientific name should be used only.
Genetic Nomenclature
Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see http://varnomen.hgvs.org/, where examples of acceptable nomenclature are provided.
Nucleotide Sequence Data
Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:
DNA Data Bank of Japan (DDBJ) http://www.ddbj.nig.ac.jp
EMBL Nucleotide Sequence Submissions http://www.ebi.ac.uk
GenBank http://www.ncbi.nlm.nih.gov
Conflict of Interest
Cell Proliferation requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. The Conflict of Interest statement should be included within the main text file of your submission.
Publications by the Editors or Editorial Board
The Editor and Editorial Board members are never involved in editorial decisions about their own work. The Editor, Editorial Board members and other editorial staff (including peer reviewers) will withdraw from discussions about submissions where any circumstances might prevent him/her offering unbiased editorial decisions. In particular, when editorial decisions are required about peer reviewed articles where the Editor or Editorial Board member is an author or is acknowledged as a contributor, the affected Editor or Editorial Board member will exclude themselves and are not involved in the publication decision. When the Editor is presented with papers where their own interests may impair their ability to make an unbiased editorial decision, decisions about the paper are deputised to a suitably qualified individual.
Funding
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: http://www.crossref.org/fundingdata/registry.html
Authorship
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
1) Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2) Been involved in drafting the manuscript or revising it critically for important intellectual content;
3) Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4) Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.
Additional authorship options
Joint first or senior authorship: In the case of joint first authorship a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’
ORCID
As part of our commitment to supporting authors at every step of the publishing process, Cell Proliferation requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information.
Refer and Transfer Program
Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program.
If your manuscript is not accepted, you may receive a recommendation to transfer the manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant.
Publication Ethics
Cell Proliferation is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at https://authorservices.wiley.com/ethics-guidelines/index.html
Supporter Journal
This journal works together with Wiley’s Open Access Journal, Health Science Reports to enable rapid publication of good quality research that is unable to be accepted for publication by our journal. Authors may be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Health Science Reports. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Health Science Reports will accept submissions that report well-conducted research that reaches the standard acceptable for publication. Health Science Reports is a Wiley Open Access journal and article publication fees apply. For more information please visit the Open Access page.
Cell Proliferation is an Open Access journal, so authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and to identify as the original publisher.
Open Access fees: Information on the Article Publication Charge for publishing in the journal is available here.
If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
To find out which Creative Commons Licences are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate that a particular type of CC license has to be used; to check these please click here.
Accepted article received in production
When your accepted article is received by Wiley’s production team, you (corresponding author) will receive an email asking you to login or register with Author Services. You will be asked to sign a publication license at this point.
Proofs
Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. No special software is required, all common browsers are supported. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Poofs must be returned within 48 hours of receipt of the email. Return of proofs via e-mail is possible in the evant that the online system cannot be used or accessed.
eLocators
This journal now uses eLocators. For more information, please visit the Author Services eLocator page here.
Early View
The journal offers rapid publication via Wiley’s Early View service. Early View(Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Before we can publish an article, we require a signed license and for the Article Publication Charge to be paid (authors should login or register with Wiley Author Services to do this.) Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.
Now is the time to start promoting your article. Find out how to do that here. Wiley also helps you measure the impact of your research through our specialist partnerships with Kudos and Altmetric.
Article Promotion Support
Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.
Email: CPReditorialoffice@wiley.com
Author Guidelines updated on 28th Sept. 2023